Fig. 3From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a reviewNeuropsychiatric adverse events occurring before day 29 in P. vivax patients given tafenoquine/chloroquine versus placebo/chloroquine [9, 10]Back to article page